Bacillus clausii-associated bacteremia following probiotic use: A report of two cases and a review of the literature.
- 1Department of Medicine, Division of Health Sciences, Hospital Universidad del Norte and Universidad del Norte, Km 5 via Puerto Colombia, Barranquilla, Colombia.
- 2Department of Public Health, Division of Health Sciences, Universidad del Norte, Km 5 via Puerto Colombia, Barranquilla, Colombia.
Abstract
Bacillus clausii bacteremia is a rare but clinically significant complication associated with probiotic use in hospitalized patients. We report two cases in which a clear temporal relationship was observed between probiotic administration and subsequent isolation of B. clausii from blood cultures. In both patients, identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), identifying B. clausii, consistent with the microorganism contained in the administered probiotic. Comprehensive clinical evaluation did not identify an alternative source specifically accounting for the isolation of B. clausii. Although B. clausii bacteremia was microbiologically documented in both cases, its contribution to clinical deterioration and death in the second patient could not be established because of severe concomitant infections and other competing conditions. Both patients had significant comorbidities, recent exposure to broad-spectrum antibiotics, and clinical conditions potentially associated with impaired gastrointestinal barrier integrity, factors that may facilitate bacterial translocation and support the biological plausibility of probiotic-associated bacteremia. Although strain-specific evidence suggests that some probiotics, including B. clausii, may reduce antibiotic-associated diarrhea, these potential benefits should be weighed against the risk of invasive infection in vulnerable patients. These cases highlight the importance of individualized risk-benefit assessment when prescribing probiotics in vulnerable hospitalized patients.
Related
- Persistent Bacillus cereus bacteremia in a patient with systemic sclerosis-associated intestinal pseudo-obstruction: A case report.
- Supplementation of Bacillus cereus Enhances Anti-Colitis Effects of Triple Probiotics in Mice: Correlative Evidence for a Gut Microbiota–Spermidine-Related Axis in Quadruple-Probiotic Protection
- Bacteroides fragilis Abscess Associated With Fat Necrosis Following Breast Augmentation With Autologous Fat Grafting: A Case Report With Review of the Literature.
- Probiotic-Enriched Yogurt with Encapsulated Lacticaseibacillus rhamnosus and Bacillus clausii: Product Characterization and Quality of Life Assessment in Type 2 Diabetes
- Vibrio parahaemolyticus bacteremia in decompensated cirrhosis complicated by spontaneous bacterial peritonitis following occupational seafood exposure: A case report.
BibTeX
@article{sanchez2026bacillus,
title = {{Bacillus clausii-associated bacteremia following probiotic use: A report of two cases and a review of the literature.}},
author = {Samuel Jesus Borrero Sanchez and Mariana Quintero Carbono and Juan Jose Espitia De La Hoz and Hugo Andrés Macareno Arroyo},
journal = {IDCases},
year = {2026},
month = oct,
doi = {10.1016/j.idcr.2026.e02792},
url = {https://europepmc.org/article/MED/42921365},
note = {CC BY},
}
RIS
TY - JOUR
TI - Bacillus clausii-associated bacteremia following probiotic use: A report of two cases and a review of the literature.
AU - Samuel Jesus Borrero Sanchez
AU - Mariana Quintero Carbono
AU - Juan Jose Espitia De La Hoz
AU - Hugo Andrés Macareno Arroyo
PY - 2026
DA - 2026/10/10
JO - IDCases
DO - 10.1016/j.idcr.2026.e02792
UR - https://europepmc.org/article/MED/42921365
AB - Bacillus clausii bacteremia is a rare but clinically significant complication associated with probiotic use in hospitalized patients. We report two cases in which a clear temporal relationship was observed between probiotic administration and subsequent isolation of B. clausii from blood cultures. In both patients, identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), identifying B. clausii, consistent with the microorganism contained in the administered probiotic. Comprehensive clinical evaluation did not identify an alternative source specifically accounting for the isolation of B. clausii. Although B. clausii bacteremia was microbiologically documented in both cases, its contribution to clinical deterioration and death in the second patient could not be established because of severe concomitant infections and other competing conditions. Both patients had significant comorbidities, recent exposure to broad-spectrum antibiotics, and clinical conditions potentially associated with impaired gastrointestinal barrier integrity, factors that may facilitate bacterial translocation and support the biological plausibility of probiotic-associated bacteremia. Although strain-specific evidence suggests that some probiotics, including B. clausii, may reduce antibiotic-associated diarrhea, these potential benefits should be weighed against the risk of invasive infection in vulnerable patients. These cases highlight the importance of individualized risk-benefit assessment when prescribing probiotics in vulnerable hospitalized patients.
SN - 2214-2509
ER -